Target intelligence / Profile preview

MAX dimerization protein 1 (MXD1)

Target
MXD1
Molecular classification
Transcription factor, Basic helix-loop-helix leucine zipper (bHLHZip) family, MAX dimerization proteins
01

Overview

MAX dimerization protein 1 (MXD1), also known as MAD or MAD1, is a transcription factor in the MYC/MAX/MAD network, characterized by a basic helix-loop-helix leucine zipper domain (bHLHZip) that mediates DNA binding and dimerization with MAX. MXD1 functions as a transcriptional repressor, antagonizing MYC-driven gene activation by competing for MAX binding and recruiting corepressor complexes such as those containing histone deacetylases. It thus acts as a regulator of cellular proliferation, differentiation, apoptosis, and ribosome biogenesis. MXD1's tumor suppressor function has been implicated in several cancers, and loss or dysregulation of MXD1 can contribute to tumorigenesis, chemoresistance, and altered cytokine expression. No drugs currently target MXD1 directly, but it regulates the molecular response to agents such as imatinib and cisplatin through repression of driver genes and interaction with major signaling pathways.

Other names
MADMAD1Max dimerizer 1Protein MADBHLHC58Max dimerization protein 1max-binding proteinantagonizer of myc transcriptional activity
02

Mechanism of action

Not directly drug-targeted; mechanisms described refer to gene expression modulation, e.g.: - Repression of BCR-ABL1 (modulates imatinib sensitivity in CML) - Repression of PTEN gene expression (modulates cisplatin sensitivity in osteosarcoma)

03

Biological functions

Transcriptional repressionAntagonism of MYC-mediated transcriptionRegulation of cell proliferationRegulation of cell differentiationRegulation of apoptosisControl of ribosome biogenesisRegulation of telomerase/TERT promoter activity
04

Disease associations

Cancer (including chronic myeloid leukemia, esophageal squamous cell carcinoma, breast cancer, osteosarcoma)Tumor suppressionDrug resistance (e.g., imatinib resistance in leukemia, cisplatin resistance in osteosarcoma)Possibly others (by regulation of cell cycle and apoptosis)
05

Safety considerations

No specific safety concerns or therapeutic challenges detailed for directly targeting MXD1, but as a transcriptional regulator its modulation could affect cell cycle, proliferation, and differentiation broadly, raising toxicity risks
06

Interacting drugs

None directly listed; imatinib resistance and cisplatin resistance are associated with MXD1 status (no direct MXD1-binding drugs identified in current search)
07

Biomarkers

No direct, clinically established biomarkers for patient selection or efficacy monitoring; altered MXD1 expression is a candidate biomarker for prognosis or drug resistance (e.g., leukemia, osteosarcoma)

Beyond the preview

Go deeper on MAX dimerization protein 1 (MXD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAX dimerization protein 1 (MXD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call